GGrantIndex
← Leaderboards

Derek A Persons

St. Jude Children'S Research Hospital

$6,676,571
Attributed
$6,676,571
Total exposure
7
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.5M · FY200514
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$7,429,483 · 8

By mechanism

U54$3,743,867 · 4
P01$2,853,260 · 2
K08$494,856 · 1
R01$337,500 · 1

Top collaborators

No co-investigators on record.

Most similar at St. Jude Children'S Research Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Gene Therapy

Research focus

Gene TherapyGlobinHematopoietic Stem CellsSickle Cell AnemiaVectorCellsLentivirus VectorBone MarrowGene ExpressionGene TransferGenesErythroid CellsBone Marrow TransplantationDisease /Disorder ModelStem CellsResearch StudySuccessHematological DiseaseMediatingErythroidFundingEngraftmentInheritedDisability

Grant awards (24)

Gene therapy of sickle cell disease through enhancement of fetal hemoglobin$365,044
P01 · FY2014 · HL · contact PI
Gene therapy of sickle cell disease through enhancement of fetal hemoglobin$342,064
P01 · FY2013 · HL · contact PI
Gene therapy of sickle cell disease through enhancement of fetal hemoglobin$355,470
P01 · FY2012 · HL · contact PI
Comprehensive Sickle Cell Center Composite:Basic & Translational Research Program$752,912
U54 · FY2011 · HL · contact PI
Hematopoietic stem cell gene therapy for sickle cell disease$365,003
U54 · FY2011 · HL · contact PI
Gene therapy of sickle cell disease through enhancement of fetal hemoglobin$348,060
P01 · FY2011 · HL · contact PI
Gene therapy of sickle cell disease through enhancement of fetal hemoglobin$352,713
P01 · FY2010 · HL · contact PI
Hematopoietic stem cell gene therapy for sickle cell disease$304,279
U54 · FY2009 · HL · contact PI
Hematopoietic stem cell gene therapy for sickle cell disease$548,197
U54 · FY2008 · HL · contact PI
CORE--VECTOR PRODUCTION$218,459
P01 · FY2008 · HL · contact PI
Gamma Globin Gene Therapy Using In Vivo Selection$423,476
U54 · FY2007 · HL · contact PI
CORE--VECTOR PRODUCTION$222,271
P01 · FY2007 · HL · contact PI
Gamma Globin Gene Therapy Using In Vivo Selection$337,500
U54 · FY2006 · HL · contact PI
CORE--VECTOR PRODUCTION$222,821
P01 · FY2006 · HL · contact PI
Gamma Globin Gene Therapy Using In Vivo Selection$337,500
U54 · FY2005 · HL
CORE--VECTOR PRODUCTION$216,329
P01 · FY2005 · HL
Gamma Globin Gene Therapy Using In Vivo Selection$337,500
U54 · FY2004 · HL
CORE--VECTOR PRODUCTION$210,029
P01 · FY2004 · HL
Y-Globin Gene Therapy Using In Vivo Selection$337,500
U54 · FY2003 · HL
GAMMA GLOBIN VECTORS FOR TREATMENT OF HEMOGLOBINOPATHIES$123,714
K08 · FY2003 · HL
Selectable Gamma-Globin Lentiviral Vectors for SCD$337,500
R01 · FY2002 · HL
GAMMA GLOBIN VECTORS FOR TREATMENT OF HEMOGLOBINOPATHIES$123,714
K08 · FY2002 · HL
GAMMA GLOBIN VECTORS FOR TREATMENT OF HEMOGLOBINOPATHIES$123,714
K08 · FY2001 · HL
GAMMA GLOBIN VECTORS FOR TREATMENT OF HEMOGLOBINOPATHIES$123,714
K08 · FY2000 · HL